Repare Therapeutics Is A Clinical Stage Precision Oncology Company Based In Quebeccanadafounded In 2016The Company Focuses On Discovering And Developing Novel Therapeutics Through A Proprietary Synthetic Lethality Approachtargeting Genomic Instability And Dna Damage Repair Utilizing Its Crispr Enabled Sniprxaplatformrepare Therapeutics Systematically Identifies And Validates Targets For Cancer Therapiesthe Company Has A Diverse Product Pipeline Aimed At Addressing Cancers With Significant Unmet Medical Needs And Is Actively Engaged In Clinical Trials For These Candidatesrepare Therapeutics Is Also Involved In Strategic Partnershipsincluding The Out Licensing Of Its Discovery Platforms To Dcx Biotherapeutics Listed On The Nasdaq Under The Ticker Symbol Rptxrepare Therapeutics Operates With A Team Of 51 To 200 Employees And Has Additional Operations In Switzerlandthe Company Is Committed To Advancing Cancer Treatment Through Innovative Research And Development
